trial

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

NCTId NCT00921804
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 296 (actual)
Sponsored by AstraZeneca
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
296 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2009-06
Primary completion
2010-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AZD 8529Risperidone

Sponsors

AstraZenecaLead Sponsor

Investigators

2
Robert C Smith, M.D., Ph.DPrincipal Investigator
Mark SmithStudy Director

Sites

3 total
Garden Grove, United StatesGlendale, United StatesRockville, United States

Linked catalysts

1
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schiz — primary completion2010-05

Facts & assertions

4 sourced
Enrollment
296
Phase
PHASE2
Primary Completion Date
2010-05
Status
COMPLETED
relationships
The graph out of here
drug
AZD 8529
drug
Risperidone
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Hallucinations
indication
Schizophrenia
indication
investigator
Robert C Smith, M.D., Ph.D
person
Mark Smith
person